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Objectives The purpose of this study was to compare the efficacy of beta-blockers in congenital long QT syndrome (LQTS).
Background Beta-blockers are the mainstay in managing LQTS. Studies comparing the efficacy of commonly used beta-
blockers are lacking, and clinicians generally assume they are equally effective.
Methods Electrocardiographic and clinical parameters of 382 LQT1/LQT2 patients initiated on propranolol (n  134),
metoprolol (n  147), and nadolol (n  101) were analyzed, excluding patients 1 year of age at beta-blocker
initiation. Symptoms before therapy and the first breakthrough cardiac events (BCEs) were documented.
Results Patients (56% female, 27% symptomatic, heart rate 76  16 beats/min, QTc 472  46 ms) were started on
beta-blocker therapy at a median age of 14 years (interquartile range: 8 to 32 years). The QTc shortening with
propranolol was significantly greater than with other beta-blockers in the total cohort and in the subset with
QTc 480 ms. None of the asymptomatic patients had BCEs. Among symptomatic patients (n  101), 15 had
BCEs (all syncopes). The QTc shortening was significantly less pronounced among patients with BCEs. There was
a greater risk of BCEs for symptomatic patients initiated on metoprolol compared to users of the other 2 beta-
blockers combined, after adjustment for genotype (odds ratio: 3.95, 95% confidence interval: 1.2 to 13.1, p 
0.025). Kaplan-Meier analysis showed a significantly lower event-free survival for symptomatic patients receiving
metoprolol compared to propranolol/nadolol.
Conclusions Propranolol has a significantly better QTc shortening effect compared to metoprolol and nadolol, especially in
patients with prolonged QTc. Propranolol and nadolol are equally effective, whereas symptomatic patients
started on metoprolol are at a significantly higher risk for BCEs. Metoprolol should not be used for symp-
tomatic LQT1 and LQT2 patients. (J Am Coll Cardiol 2012;60:2092–9) © 2012 by the American College of
Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.046Ludwig-Maximilians-University, Klinikum Grosshadern, Munich, Germany; ††De-
partment of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden; ‡‡De-
partment of Pediatric Cardiology, University Hospital of Heidelberg, Heidelberg,
Germany; §§Department of Pediatric Cardiology, Beatrix Children’s Hospital,
University Medical Centre Groningen, Groningen, the Netherlands;  Department
of Pediatric Cardiology, Leiden University Medical Centre, Leiden, the Netherlands;
¶¶Cardiovascular Genetics Laboratory, Hatter Institute for Cardiovascular Research,
Department of Medicine, University of Cape Town, Cape Town, South Africa; and
the ##Department of Family and Community Medicine, College of Medicine, KingFrom the *Department of Cardiology, Heart Failure Research Centre, Academic
Medical Centre, Amsterdam, the Netherlands; †Department of Pediatric Cardiology,
Emma Children’s Hospital, Academic Medical Centre, Amsterdam, the Netherlands;
‡Department of Molecular Medicine, University of Pavia and Fondazione IRCCS
Policlinico S. Matteo, Pavia, Italy; §Department of Cardiology, IRCCS Fondazione
Policlinico S. Matteo, Pavia, Italy; Institute of Human Genetics, Helmholtz
Zentrum, Munich, Germany; ¶Departments of Medicine, Pediatrics, and Molecular
Pharmacology and Experimental Therapeutics, Divisions of Cardiovascular Diseases
and Pediatric Cardiology and the Windland Smith Rice Sudden Death Genomics
Laboratory, Mayo Clinic, Rochester, Minnesota; #Department of Cardiology, Uni-
versity Medical Centre, Utrecht, the Netherlands; **Department of Medicine 1,
Saud University, Riyadh, Saudi Arabia. The research programs of Drs. Wilde and
Kääb are supported by the Leducq program grant Alliance Against Sudden Cardiac
n
W
t
b
i
D
d
p
t
e
c
o
s
(
t
t
s
m
t
T
t
m
u
c
(
t
b
d
fi
b
i
i
d
t
B
2093JACC Vol. 60, No. 20, 2012 Chockalingam et al.
November 13, 2012:2092–9 Dissimilar Efficacy of Beta-Blockers in LQTSCongenital long QT syndrome (LQTS) is a primary inherited
arrhythmia syndrome associated with an increased propensity to
arrhythmogenic syncope and sudden death. Abnormal cardiac
repolarization evident as prolonged QT interval on the electrocar-
diogram (ECG) is the signature feature of LQTS. Since the
1970s, beta-blockers have been the mainstay in managing this
disorder primarily because the trigger for most life-threatening
arrhythmias is a sudden increase in sympathetic activity,
especially in LQT1 and LQT2 patients (1,2).
See page 2100
The efficacy of beta-blockers in reducing LQTS-associated
cardiac events is established (3,4). Propranolol, the prototypic
beta-blocking agent, has been studied most extensively and has
been shown to either decrease or prevent an increase in transmural
dispersion of repolarization in response to strong sympathetic
stimulation, a mechanism contributing to its antiarrhythmic effect
(5). Although several studies have clearly demonstrated a very
favorable response to beta-blockers in symptomatic LQTS
patients, it is also evident that 20% to 30% of previously
symptomatic patients experience a breakthrough cardiac
event (BCE) while receiving beta-blocker therapy (6 – 8).
Concern that not all beta-blockers provide equivalent
protection in LQTS and that this could contribute to
treatment failure has been expressed in the past (9,10).
However, actual comparisons between different beta-
blockers are lacking. Recent findings concerning the
differential mechanism of action of propranolol and
metoprolol on the cardiac sodium (Na) channel have
thrown light on the probable physiology underlying this
significant therapeutic aspect (11). The purpose of this
study was to compare the efficacy of commonly used
beta-blockers in LQTS by comparing the baseline and
on-therapy clinical and electrocardiographic characteris-
tics of patients treated with different beta-blockers and by
correlating this with the occurrence of BCEs on
follow-up.
Methods
Study population. LQTS patients, both index patients and
family members, managed at the participating university
hospitals were included if they had a genetically confirmed
LQT1 or LQT2 mutation, were initiated on therapy with
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accepted July 24, 2012.beta-blockers, and had at least 1
pre-therapy (baseline) and 1 on-
therapy ECG for review. Pa-
tients diagnosed with LQTS and
initiated on beta-blocker therapy
in their first year of life were not
included in the study. Patients
with LQT3-13 or multiple mu-
tations were not included. Pa-
tients lost to follow-up after ini-
tial evaluation (n  9) and
patients with history of QTc-
prolonging drug intake at the
time of baseline evaluation (n 
3) were excluded from the study.
A total of 382 patients started on
therapy with propranolol (n 
134), metoprolol (n  147), and
adolol (n 101) were included.
e did not include patients
reated with other beta-blockers
ecause of small patient numbers, which might have led to
ncorrect inferences.
ata collection and management. Demographic data and
etails of personal and family history were obtained for all
atients. Syncope (defined as transient loss of consciousness
hat was abrupt in onset and offset), near drowning, seizure
pisodes with associated loss of consciousness, and aborted
ardiac arrest (ACA, requiring external defibrillation as part
f resuscitation) were considered pertinent LQTS-related
ymptoms. The last ECG before initiation of beta-blockers
baseline) and the first available ECG after initiation of
herapy (on-therapy) were retrieved for analysis, and the
ime interval between the 2 was documented.
The ECG analyses were performed by experienced phy-
icians blinded to therapy details. The QT interval was
easured manually from the beginning of the QRS complex
o the end of the T-wave in lead II or V5. The end of the
-wave was determined as the intersection point between
he isoelectric baseline and the tangent representing the
aximal downward slope of the positive T-wave or maximal
pward slope of the negative T-wave. The mean of 3
onsecutive QT intervals was used. Corrected QT interval
QTc) was obtained using Bazett’s formula. For purposes of
his study, QTc was considered normal if 450 ms,
orderline if 451 to 480 ms, and prolonged if 480 ms.
Follow-up data on beta-blockers included the initiation
ate, date of switch to another beta-blocker (considering
rst switch if switched more than once), date of beta-
locker discontinuation (if applicable), and details of BCEs
f any. A BCE was defined as syncope, ACA, appropriate
mplantable cardioverter defibrillator (ICD) shock, or sud-
en cardiac death occurring while receiving beta-blockers,
aking into account the first BCE for subjects with multiple
CEs. Beta-blocker compliance and the nonusage of other
Abbreviations
and Acronyms
ACA  aborted cardiac
arrest
BCE  breakthrough
cardiac event
ECG  electrocardiogram
ICD  implantable
cardioverter defibrillator
IQR  interquartile range
LCSD  left cardiac
sympathetic denervation
LQTS  long QT syndrome
LQT1  long QT syndrome
type 1
LQT2  long QT syndrome
type 2
QTc  heart rate corrected
QT intervalT-prolonging drugs at the time of the BCEs had been
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Dissimilar Efficacy of Beta-Blockers in LQTS November 13, 2012:2092–9verified by the caring physicians. Any BCEs occurring at a
time of admitted noncompliance were not included. Details
of ancillary LQTS therapy with ICD, pacemaker, and/or
surgical left cardiac sympathetic denervation (LCSD) were
documented.
Statistical analysis. Continuous variables are presented as
mean SD and analyzed by t test for independent or paired
samples, as appropriate, and by 1-way analysis of variance,
according to the number of groups compared, with Bonfer-
roni correction for multiple comparisons. Whenever the
distribution was skewed, continuous variables, presented as
median and interquartile range (IQR), were compared by
Mann-Whitney and Kruskal-Wallis tests. Categorical vari-
ables are presented as number of patients (n) and/or
percentage (%) and analyzed by the chi-square test. Ad-
justed odds ratio with 95% confidence interval was esti-
mated from a multivariate logistic regression model used to
determine the association between beta-blockers and occur-
rence of BCEs in previously symptomatic patients, while
controlling for genotype. Kaplan-Meier analysis, with log-
rank test for comparisons, was used to estimate the cumu-
lative event-free survival of symptomatic patients, taking the
first BCE as the endpoint. However, if beta-blocker switch
occurred before BCE, censoring was done at the time of
switch. In patients without a BCE, censoring was done at
the time of beta-blocker switch or at the time of beta-
blocker discontinuation or at the time of the study, which-
ever came first. All analyses were performed using SPSS
version 18.0 (SPSS, Inc., Chicago, Illinois), and p  0.05
was considered statistically significant.
Results
Clinical characteristics of the study subjects (n  382)
started on the different beta-blockers are provided in Table 1.
Clinical Characteristics of Patients on Basis ofTable 1 Clinical Characteristics of Patients
Characteristics
Total
(n  382)
P
(
Female 215 (56) 6
Symptoms before therapy
Syncope 90 (24) 4
ACA 11 (3)
Genotype
LQT1 207 (54) 7
LQT2 175 (46) 5
Baseline HR, beats/min 76 16
Baseline QTc, ms 472 46 4
Median age at start of BB, yrs 14 (8–32) 1
On-therapy HR, beats/min 64 14
On-therapy QTc, ms 454 39 4
Median TI, months 8 (4–13)
HR, beats/min 11 12
QTc, ms 18 34
Values are n (%), mean  SD, or median (interquartile range). *p  0
ACA  aborted cardiac arrest; BB  beta-blocker; HR  heart rate; TI  tim
change in electrocardiography parameter with beta-blocker initiation.Females constituted 56% of the study population. Symp-
toms before treatment were present in 27% of the subjects,
with syncope being the most common symptom. There
were more LQT1 patients (54%) than LQT2 patients
(46%) in the total cohort. The distribution of sex, genotype,
and symptomatic patients was different among the beta-
blocker groups. The baseline heart rate of the study popu-
lation was 76  16 beats/min and was comparable among
the beta-blocker groups; the baseline QTc was 472 46 ms
and was different among the beta-blocker groups. Median
age at beta-blocker initiation was 14 years (IQR: 8 to 32
years) in the total cohort, and differed among the 3 groups.
The on-therapy heart rate and QTc were different com-
pared to the baseline heart rate and QTc within each
beta-blocker group (p  0.001 for all paired comparisons).
However, while the change in heart rate with beta-blocker
initiation was comparable among the groups (p  0.9), the
change in QTc with propranolol was greater than that with
metoprolol (p  0.003) and with nadolol (p  0.004).
Median initial beta-blocker dosages documented at the
time of on-therapy ECG were propranolol, 1.8 mg/kg
daily (IQR: 1.2 to 2 mg/kg daily); metoprolol, 0.9 mg/kg
daily (IQR: 0.7 to 1.6 mg/kg daily); and nadolol, 0.9
mg/kg daily (IQR: 0.7 to 1.2 mg/kg daily). Regular
propranolol was used by 99% of propranolol users and
sustained-release metoprolol by 90% of metoprolol users.
QTc shortening on the basis of baseline QTc. Given the
longer baseline QTc in the propranolol group compared to
the other groups, and the appearance of dependence of QTc
shortening on the baseline QTc, all subjects were further
subdivided on the basis of whether the baseline QTc was
normal (450 ms), borderline (451 to 480 ms) or prolonged
(480 ms) (Fig. 1). The baseline heart rate differed among
beta-blocker groups within the normal QTc subset, and the
l Beta-Blockerasis of Initial Beta-Blocker
olol
34)
Metoprolol
(n  147)
Nadolol
(n  101) p Value
) 94 (64) 56 (55) 0.03
) 30 (20) 14 (14) 0.001
5 (3) 1 (1) 0.4
0.001
) 59 (40) 69 (68)
) 88 (60) 32 (32)
18 75 15 74 13 0.06
47* 469 49 465 40 0.03
2) 21 (11–38) 14 (9–30) 0.001
16 64 12 62 13 0.05
37 456 44 452 34 0.8
13) 6 (3–13) 12 (8–14) 0.001
12 11 12 11 12 0.9
8† 14 34 12 28 0.001
sus nadolol; †p  0.01 versus metoprolol and versus nadolol.Initiaon B
ropran
n  1
5 (49
6 (34
5 (4)
9 (59
5 (41
78
80
0 (6–2
67
53
8 (3–
12
27 3
.05 ver
e interval between baseline and on-therapy electrocardiograms; 
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November 13, 2012:2092–9 Dissimilar Efficacy of Beta-Blockers in LQTSage at therapy initiation differed within the normal and
prolonged QTc subsets. Now, the baseline QTc was expect-
edly comparable within all 3 QTc subsets. The QTc
shortening with propranolol, metoprolol, and nadolol in the
normal QTc subset (0  27 ms, 1  23 ms, 2  20 ms;
 0.8) and in the borderline QTc subset (22  23 ms,
1 29 ms, 18 26 ms; p 0.2) were comparable but was
ignificantly different in the prolonged QTc subset (49 42
ms, 30  40 ms, 27  29 ms; p  0.01). Bonferroni test
showed the QTc shortening with propranolol to be different
from that with metoprolol (p 0.04) and with nadolol (p
0.04) in the prolonged QTc subset.
Progression of QTc in subjects switched from propranolol
to metoprolol. A subset of patients (n  14, from 2
participating centers) initiated on propranolol and switched
to metoprolol during follow-up were retrospectively ana-
lyzed to study QTc progression (Fig. 2). In this subset, there
were 11 LQT1 patients and 3 LQT2 patients. Median age
at start of propranolol was 6 years (IQR: 6 to 7 years), and
median age at switch to metoprolol was 11 years (IQR: 9 to
13 years). On-therapy QTc (447 20 ms) with propranolol
measured at a median time of 7 months (IQR: 5 to 10
months) after initiation differed significantly from the base-
line QTc (465  29 ms, p  0.005). The QTc on
etoprolol (464  39 ms) measured at a median time of 12
onths (IQR: 6 to 18 months) after the switch was
ignificantly longer than the QTc on propranolol (445 28
s) measured at a median time of 18 months (IQR: 12 to
8 months) before the switch (p  0.004).
omparison of LQT1 and LQT2 subjects. A similar
roportion of LQT1 and LQT2 subjects were symptomatic
efore therapy (Table 2). While baseline heart rate was
omparable between the genotypes, LQT2 subjects had a
Figure 1 Effect of Baseline QTc on QTc Shortening
Baseline QTc was taken as normal if 450 ms, borderline if 451 ms to 480
ms, and prolonged if 480 ms. The  indicates change in electrocardiography
parameter with beta-blocker initiation. Blue bars indicate propranolol; red bars
indicate metoprolol; green bars indicate nadolol.onger baseline QTc (p 0.01) than LQT1 subjects. Age ateta-blocker initiation was greater (p  0.04) in LQT2
subjects. Overall QTc shortening and that due to initiation
of propranolol, metoprolol, and nadolol were comparable
between the genotypes.
Analysis of occurrence of BCEs on the basis of symptoms
before treatment. Among asymptomatic subjects (n 
281), 30% were initiated on propranolol, 40% on meto-
prolol, and 30% on nadolol. There were no BCEs docu-
mented during a median follow-up period of 6 years (IQR:
2 to 10 years) on propranolol, 6 years (IQR: 3 to 9 years) on
metoprolol, and 4 years (IQR: 3 to 6 years) on nadolol.
The clinical characteristics of previously symptomatic
(n  101) subjects initiated on the 3 beta-blockers are
shown in Table 3. Sex, genotype, and age at beta-blocker
initiation were comparable among the subjects in the 3
Figure 2 Progression of QTc With Initiation
of Propranolol and Switch to Metoprolol
Progression of QTc (mean  SD) with initiation of propranolol and subsequent
switch to metoprolol in a subset of 14 patients. “Baseline” indicates QTc
immediately before initiation of propranolol therapy; “propranolol” indicates
first QTc measurement on propranolol; “prior to switch” indicates QTc on pro-
pranolol before switch; “at switch” indicates QTc on propranolol at the time the
decision to switch was made; “metoprolol” indicates QTc on metoprolol after
switch; and “TI” is time interval in months.
Clinical Characteristics ofPatients on the Ba is of GenotypeTable 2 Clinic l Characteristics ofPatients on the Basis of Genotype
Characteristics
LQT1
(n  207)
LQT2
(n  175) p Value
Symptoms before therapy 56 (27) 45 (26) 0.8
Baseline HR, beats/min 77 15 74 16 0.08
Baseline QTc, ms 467 42 478 50 0.01
Median age at start of BB, yrs 12 (7–30) 18 (10–34) 0.04
HR, beats/min 11 12 11 12 0.9
QTc, ms 18 32 18 37 0.9
QTc with propranolol, ms 25 35 29 43 0.6
QTc with metoprolol, ms 16 29 12 37 0.5
QTc with nadolol, ms 11 30 14 22 0.6Values are n (%), mean  SD, or median (interquartile range).
Abbreviations as in Table 1.
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toms before treatment. With baseline and on-therapy ECG
parameters being comparable, there was an overall signifi-
cant difference (p  0.018) in the occurrence of BCEs
among the 3 beta-blocker groups (Fig. 3). All 15 BCEs
were syncopes. Median beta-blocker dosages documented at
the time of BCEs were propranolol, 2.5 mg/kg daily (IQR:
1.3 to 3 mg/kg daily), and metoprolol, 1.4 mg/kg daily
(IQR: 0.9 to 2.5 mg/kg daily). The only patient who had a
BCE while on nadolol therapy was receiving a dose of 0.8
mg/kg daily. The BCEs were more frequent among patients
using regular metoprolol at a twice-daily dosing than among
patients using sustained-release metoprolol at once-a-day
dosing (18% vs. 5%, p  0.04). There was only 1 sudden
ardiac death, which, however, did not occur as a first BCE:
previously symptomatic LQT1 male patient initiated on
ropranolol at the age of 5 years was switched to metoprolol
t the age of 8 years. He experienced a syncope (first BCE)
t the age of 11 years while playing football and died a few
Clinical Characteristics of Symptomatic PatientTable 3 Clinical Characteristics of Symptom
Characteristics
Total
(n  101)
P
Female 73 (72)
LQT1 56 (55)
Baseline HR, beats/min 74 14
Baseline QTc, ms 499 51
Median age at start of BB, yrs 22 (10–34)
On-therapy HR, beats/min 62 12
On-therapy QTc, ms 474 41
Median TI, months 6 (3–17)
HR, beats/min 12 12
QTc, ms 26 37
BCE 15 (15)
Values are n (%), mean  SD, or median (interquartile range).
BCE  breakthrough cardiac event; other abbreviations as in Table
Figure 3 Occurrence of BCEs in
Patients With Symptoms Before Therapy
Breakthrough cardiac events (BCEs) occurred in 8% of patients receiving pro-
pranolol, 7% of patients receiving nadolol, and 29% of patients receiving
metoprolol.months later of an out-of-hospital cardiac arrest (second
BCE) while swimming, still under therapy with metoprolol.
As expected, the use of an ICD (18% vs. 0.4%, p 
0.001), pacemaker (3% vs. 0.7%, p 0.09), and LCSD (7%
vs. 0%, p  0.001) differed between symptomatic and
asymptomatic subjects.
Comparison of symptomatic subjects with and without
BCE. Sex, baseline heart rate, baseline QTc, and age at
therapy initiation were comparable between symptomatic
patients with or without BCEs (Table 4). However,
symptomatic LQT2 patients had more BCEs compared
to symptomatic LQT1 patients (p  0.02). Also, patients
with BCEs had lesser QTc shortening (p  0.02) than
atients without BCEs. Median follow-up time on the
nitial beta-blocker among symptomatic subjects was 2
ears (IQR: 1 to 6 years) for propranolol, 4 years (IQR:
to 8 years) for metoprolol, and 3 years (IQR: 2 to 5
ears) for nadolol (p  0.4).
Figure 3 shows that the occurrence of BCEs was signif-
icantly different according to the initial beta-blocker used.
Indeed, while the proportion of BCEs was almost identical
(p  0.9) for symptomatic patients initiated on propranolol
the Basis of Initial Beta-BlockerPatients on the Basis of Initial Beta-Blocker
olol
1)
Metoprolol
(n  35)
Nadolol
(n  15) p Value
) 26 (74) 11 (73) 0.9
) 14 (41) 10 (67) 0.07
14 75 14 69 11 0.3
52 497 48 493 54 0.8
34) 25 (17–38) 22 (9–32) 0.2
14 61 9 60 13 0.7
40 478 44 478 35 0.5
16) 5 (2–17) 8 (3–20) 0.7
12 14 12 9 9 0.3
39 19 37 15 28 0.1
10 (29) 1 (7) 0.02
Comparison of Symptomatic Patients on theBasis of Occurrence of BCE on Initial Beta-BlockerTable 4 Comparison of Symptomatic Patients on theBasis of Occurrence of BCE on Initial Beta-Blocker
BCE on initial BB
Variable
Yes
(n  15)
No
(n  86) p Value
Female 11 (73) 62 (72) 0.9
Genotype 0.02
LQT1 4 (27) 52 (60)
LQT2 11 (73) 34 (40)
Baseline HR, beats/min 72 11 74 14 0.6
Baseline QTc, ms 488 42 501 52 0.3
Median age at start of BB, yrs 17 (14–26) 22 (10–34) 0.8
HR, beats/min 12 12 12 11 0.9
QTc, ms 4 24 30 38 0.02s onatic
ropran
(n  5
36 (71
32 (62
74
502
18 (8–
63
469
8 (3–
11
33
4 (8)Values are n (%), mean  SD, or median (interquartile range).
Abbreviations as in Tables 1 and 3.
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patients initiated on metoprolol. That corresponded to a
substantially greater risk of suffering a BCE for symptom-
atic patients initiated on metoprolol compared to patients
started on either of the other 2 beta-blockers combined
(odds ratio: 3.95, 95% confidence interval: 1.2 to 13.1, p 
0.025), after adjusting for genotype. Consequently, the
Kaplan-Meier analysis plotting symptomatic patients initiated
on metoprolol (n  35) against those initiated on propranolol
and nadolol combined (n 66) showed a significant difference
(p 0.02) in the cumulative event-free survival of the patients
(Fig. 4). Indeed, by 10 years on beta-blocker therapy, the
cumulative event-free survival for propranolol/nadolol users
was 91% compared to 60% for metoprolol users.
Discussion
Contrary to the currently prevailing views, in the management
of LQTS, not all beta-blockers are equal. The main finding of
the present study is that symptomatic patients treated with
metoprolol are 4 times more likely to have BCEs than those
treated with propranolol and nadolol. This finding will un-
avoidably impact the clinical management of LQTS. The
other major finding of this study is the evidence for a
correlation between the antiarrhythmic efficacy of beta-
blockers and their ability to shorten the QT interval.
LQTS, beta-blockers, Na channel block, and QTc
hortening. LQTS is a genotypically and phenotypically
eterogeneous disease. The mortality rate among untreated
Figure 4
Kaplan-Meier Estimates of
Event-Free Survival of Symptomatic
Patients Initiated on Different Beta-Blockers
The cumulative event-free survival of symptomatic patients initiated on meto-
prolol (n  35) (red line) was significantly different (p  0.02) from that of
patients initiated on propranolol and nadolol combined (n  66) (green line).ymptomatic LQTS patients was as high as 60% to 65%
hen the first assessment of the beneficial effect of beta-
lockers in a large group of patients was made in 1975 (1).
ince then, beta-blockers, the mainstay of therapy in
QTS, have been highly effective in reducing mortality
4,10). Whereas propranolol and nadolol are nonselective
eta-blockers, metoprolol is relatively beta-1 cardioselective.
he largest experience with beta-blockers in LQTS has
een that with propranolol. Its main advantages are the
ood tolerability and the lipophilia that allows it to cross the
lood brain barrier, while the need for multiple daily dosing
ue to its rapid metabolization is the prime disadvantage.
lthough long-acting, sustained-release preparations of
ropranolol exist, they are not available in a form suitable
or use in children. To overcome the inconvenient dosing
chedule with propranolol, an increasing number of patients
ave been treated with longer-acting beta-blockers such as
adolol and sustained-release metoprolol. Ancillary LQTS
herapy in the form of ICD, pacemaker, and/or LCSD is
eserved for patients with symptoms despite beta-blockers
nd for high-risk patients (12). Additionally, when nonse-
ective beta-blockers are contraindicated, for example, for
sthma patients, LCSD has been performed with excellent
esults (unpublished data).
In some of the participating centers, it is common
ractice to initiate treatment with propranolol or nadolol
on the basis of availability) in young children mainly
ecause of their proven safety for this age group of patients.
ropranolol users are quite often switched to another
eta-blocker during adolescence to optimize compliance.
imilarly, sustained-release metoprolol is used as the initial
eta-blocker in adults mainly because of its dosing conve-
ience. These policies explain to some extent the lesser age
t therapy initiation for propranolol and nadolol compared
o metoprolol. We consider the difference in baseline QTc
o have been an effect of these age-based choices rather than
eing an underlying reason for therapeutic decision making.
Initial concern that all beta-blockers are not equally
rotective in LQTS, and therefore should not be viewed as
quivalent choices, was raised by Chatrath et al. (9), but the
mall size of that study has limited its impact. The current
ractice is that physicians typically choose a beta-blocker on
he basis of personal experience and then make appropriate
hanges on the basis of side effects and dosing preferences.
Both beta-adrenoceptor blocking properties and non
eta-adrenoceptor mediated actions of propranolol have
een proposed to contribute to the antiarrhythmic actions of
ropranolol (13). Although the Na channel blocking
efficacy of propranolol has been known for long, a recent
study has demonstrated that its blocking effect is particularly
more on the late noninactivating Na current than on the
peak Na current, an effect not seen with metoprolol (11).
here were no data available on nadolol earlier, but, quite
ecently, it has been found that nadolol has an 20% non
se-dependent blocking effect on peak Na current, and noeffect on the late current, whereas metoprolol has no effect
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biophysical properties of the channel revealed that both
nadolol and propranolol cause hyperpolarizing shifts on
voltage dependence of activation and steady-state inactiva-
tion, whereas metoprolol shifts only the activation curve.
These biophysical data clearly explain the differences be-
tween propranolol and metoprolol, and provide a partial
explanation for the difference between nadolol and meto-
prolol. Also, the mechanism of the similar clinical efficacy of
nadolol and propranolol is not fully understood.
It is clear that in addition to the membrane stabilizing
effect of propranolol and nadolol brought about by peak
Na current blockade, propranolol has a pronounced late
noninactivating Na current blocking ability, which con-
ributes directly to shortening of the action potential dura-
ion, and thereby the QTc. The association between QTc
hortening and reduction in cardiac events has been shown
n earlier studies (4) and is confirmed by the present study.
hough beta-blockers do not seem to act on the cardiac
otassium channels that are dysfunctional in LQT1 and
QT2, their properties are likely to contribute to a major
xtent to the drastic reduction in cardiac events in LQT1
nd LQT2 patients. The clinical implication of these
ndings is that prolonged cardiac repolarization in LQTS is
hortened more effectively by propranolol than by meto-
rolol, as the present study confirms. Indeed, by comparing
ll patients on the basis of their initial beta-blocker, we
bserved that propranolol had a significantly better QTc-
hortening effect compared to metoprolol and nadolol.
urthermore, by grouping subjects on the basis of baseline
Tc, the differences in baseline parameters were reduced,
nd we were able to make comparisons in more homoge-
ous patient subgroups. The pronounced QTc-shortening
ffect of propranolol in comparison to that of metoprolol
nd nadolol in subjects with QTc480 ms can be explained
y the net late Na inward current being largest when the
action potential duration is longer.
LQTS and efficacy of beta-blockers. Sex, QTc, and the
locus of causative mutation have all been identified as factors
influencing the clinical course of LQTS patients (2,15). In
the present study, the type of LQTS (LQT1 or LQT2) did
not influence the occurrence of symptoms before treatment
nor did it affect the QTc shortening with beta-blocker
initiation. The occurrence of BCEs was significantly influ-
enced by the occurrence of cardiac symptoms before ther-
apy, confirming previous observations (16). Although there
were no BCEs among asymptomatic patients, 15% of
symptomatic patients had BCEs while still on the initial
beta-blocker. The LQT2 genotype and modest QTc short-
ening with beta-blockers were risk factors for BCEs in this
group of patients. Goldenberg et al. (17) have shown that
male patients with LQT1 in the14 years of age group and
female patients with LQT2 in the 15 to 40 years age group
are at a high risk for cardiac events and that the risk
reduction with beta-blockers is significantly high in both
groups of patients. The present study, performed with thiscross-over phenomenon in mind, has analyzed the occur-
rence of BCEs only in the previously symptomatic patients
with comparable baseline characteristics. The clinically im-
portant finding of our study is that the incidence of first
BCEs was rather low, did not include lethal events, and was
almost identical among patients receiving propranolol (8%)
and nadolol (7%), whereas it was unacceptably high (29%)
among those treated with metoprolol. Given the evidence
that patients with syncope during beta-blocker therapy are
those at a truly high risk of life-threatening events (18), this
finding carries significant clinical implications in the man-
agement of young symptomatic LQTS patients.
Study limitations. Although this is the largest multicenter
study to date comparing the efficacy of commonly used
beta-blockers in LQTS, it has the inherent limitation of a
retrospective study, namely, lack of homogeneity among
patients treated with different beta-blockers. However,
grouping patients on the basis of their baseline QTc enabled
comparison of the QTc shortening produced by beta-
blockers in more homogeneous subgroups of patients. Fur-
ther, among previously symptomatic patients, where base-
line parameters such as sex, genotype, heart rate, QTc, and
age at therapy initiation were all comparable, we were able
to compare the BCE incidence, which was found to be
significantly more among patients initiated on 1 of the
beta-blockers. The multivariate logistic regression analysis
allowed confirmation of the higher risk of BCEs among
metoprolol users even after adjusting for genotype. How-
ever, the relatively small number of patients with BCEs and
the possibility of residual confounding are recognized as
limitations of this study.
Conclusions
This multicenter study on LQTS patients receiving beta-
blocker therapy has shown for the first time that propranolol
and nadolol are significantly more effective than metoprolol
in preventing BCEs in symptomatic patients. Also, pro-
pranolol was superior to both nadolol and metoprolol in
terms of shortening the cardiac repolarization time, partic-
ularly in high-risk patients with markedly prolonged QTc.
Symptomatic patients with BCEs had significantly less QTc
shortening than the event-free patients. As we have docu-
mented an increased risk for symptomatic patients to suffer
BCEs with metoprolol, we recommend treatment of symp-
tomatic LQT1 and LQT2 patients with either propranolol
or nadolol, as clearly not all beta-blockers are equal in their
antiarrhythmic efficacy in LQTS.
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